filmov
tv
A Discussion with Dr. Robin Carhart-Harris - TheraPsil Webinar
Показать описание
On 'Magic Mushroom Day' 9/20 (September 20th), TheraPsil hosted a webinar featuring Dr. Robin Carhart-Harris.
Robin discusses his trial of Psilocybin versus Escitalopram for Depression, published in the New England Journal of Medicine.
TheraPsil's Research Director, Julia Joyes, and CEO, Spencer Hawkswell, ask Robin questions about his thoughts on the future of psilocybin for mental health, the future of psilocybin research, and the importance of regulation change for advanced research and patient access.
Who is Dr. Robin Carhart Harris?
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. At Imperial College, he founded and lead London’s Centre for Psychedelic Research, which became the world’s first center focused exclusively on studying how psychedelics can be used in mental-health care when it opened in 2019, including designing and carrying out human brain imaging studies with a variety of psychedelic compounds, including a clinical trial comparing psilocybin with the SSRI escitalopram for major depressive disorder which was published in the New England Journal of Medicine.
Robin has published over 115 scientific papers and in 2021, he was listed in TIME magazine’s ‘100 Next’, a list of 100 rising stars shaping the future. In July 2021, Robin moved to the University of California, San Francisco, becoming the Ralph Metzner Distinguished Professor in Neurology and Psychiatry, where he will serve as Director of the new Psychedelics Division within the translational neuroscience Centre, Neuroscape.
Additional information:
Robin discusses his trial of Psilocybin versus Escitalopram for Depression, published in the New England Journal of Medicine.
TheraPsil's Research Director, Julia Joyes, and CEO, Spencer Hawkswell, ask Robin questions about his thoughts on the future of psilocybin for mental health, the future of psilocybin research, and the importance of regulation change for advanced research and patient access.
Who is Dr. Robin Carhart Harris?
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol. At Imperial College, he founded and lead London’s Centre for Psychedelic Research, which became the world’s first center focused exclusively on studying how psychedelics can be used in mental-health care when it opened in 2019, including designing and carrying out human brain imaging studies with a variety of psychedelic compounds, including a clinical trial comparing psilocybin with the SSRI escitalopram for major depressive disorder which was published in the New England Journal of Medicine.
Robin has published over 115 scientific papers and in 2021, he was listed in TIME magazine’s ‘100 Next’, a list of 100 rising stars shaping the future. In July 2021, Robin moved to the University of California, San Francisco, becoming the Ralph Metzner Distinguished Professor in Neurology and Psychiatry, where he will serve as Director of the new Psychedelics Division within the translational neuroscience Centre, Neuroscape.
Additional information:
Комментарии